Pioglitazone: Cardiovascular effects in prediabetic patients

Cardiovascular Drug Reviews

Volumn 20, Issue 4, 2002, Pages 329-340

  Mizushige, Katsufumi ^a   Tsuji, Teppei ^a   Noma, Takahisa ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Aortic distensibility; Cardiovascular function; Collagen; Diabetes; Insulin resistance; Oxidative stress; Pioglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; COLLAGEN; HYDROXYL RADICAL; INSULIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHENYL GROUP; PIOGLITAZONE; PYRIDINE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANTIOXIDANT ACTIVITY; AORTA WALL; ARTERY DILATATION; CARCINOGENICITY; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COLLAGEN SYNTHESIS; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG HYDROXYLATION; DRUG MECHANISM; DRUG METABOLISM; EDEMA; EMBRYOTOXICITY; FATTY LIVER; GLUCOSE METABOLISM; HEART LEFT VENTRICLE FILLING; HEART MUSCLE FIBROSIS; HEPATITIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER FIBROSIS; LIVER TOXICITY; MYOCARDIAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TERATOGENICITY; TISSUE INJURY; VASCULAR SMOOTH MUSCLE; WEIGHT GAIN;

ANIMALS; AORTA; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FIBROSIS; HUMANS; HYPOGLYCEMIC AGENTS; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; PREDIABETIC STATE; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0036959197     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2002.tb00100.x     Document Type: Review

References (50)

1. Abbott WG, Foley JE. Comparison of body composition, adipocyte size and glucose and insulin concentration in Pima Indian and Caucasian children. Metabolism 1987;36:576-579.
2. Aronoff S, Rosenblatt S, Braithwate S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care 2000;23:1605-1611.
3. Barra JG, Levenson J, Armentano RL, Fischer-EIC, Pichel RH, Simon A. In vivo angiotensin II receptor blockade and converting enzyme inhibition on canine aortic viscoelasticity. Am J Physiol 1997;272: H859-H868.
4. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-412.
5. Boden G Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1996;45:3-10.
6. Boelsterli UA, Bedoucha M. Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPARγ) expression in the liver: Insights from models of obesity and type 2 diabetes. Biochem Pharmacol 2002;63:1-10.
7. Buchanan TA, Meehan WP, Jeng YY, et al. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 1995;96:354-360.
8. Celetano A, Vaccaro O, Tammaro P, et al. Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. Am J Cardiol 1995;76:1173-1176.
9. Elcock FJ, Lyon JJ, Hitchcock J, Morgan DG, Bertram TA, Bugelski PJ. Toxicity of troglitazone in cultured rat hepatocytes. Diabetes 1999;78(Suppl 1):A63.
10. Fukui T, Noma T, Mizushige K, Aki Y, Kimura S, Abe Y. Dietary troglitazone decreases oxidative stress in early stage type II diabetic rats. Life Sci 1999;66:2043-2049.
11. Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy. Am J Cardiol 1991;68:85-89.
12. Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000;60:333-343.
13. Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998;129:36-38.
14. Hamaguchi A, Kim S, Ohta K, et al. Transforming growth factor-β1 expression and phenotypic modulation in the kidney of hypertensive rats. Hypertension 1995;26:199-207.
15. Hickler RB. Aortic and large artery stiffness: Current methodology and clinical correlations. Clin Cardiol 1990;13:317-322.
16. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-2415.
17. Hurrell DG, Nishimura RA, Ilstrup DM, Appleton CP. Utility of preload alteration in assessment of left ventricular filling pressure by Doppler echocardiography: A simultaneous catheterization and Doppler echocardiographic study. J Am Coll Cardiol 1997;30:459-467.
18. Ikeda H, Taketomi S, Sugiyama Y, et al. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung 1990;40:156-162.
19. Inoue I, Katayama S, Takahashi K, et al. Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun 1997;235:113-116.
20. Joki N, Kaname S, Hirakata M, et al. Tyrosine-kinase dependent TGF-beta and extracellular matrix expression by mechanical stretch in vascular smooth muscle cells. Hypertens Res 2000;23:91-99.
21. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications, Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992;41:1422-1428.
22. Kiyota Y, Kondo T, Maeshiba Y, et al. Studies on the metabolism of the new antidiabetic agent pioglitazone. Identification of metabolites in rats and dogs. Arzneimittelforschung 1997;47:22-28.
23. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3452-3456.
24. Kyaw M, Yoshizumi M, Tsuchiya K, Kirima K, Tamaki T. Antioxidants inhibit JNK and p38 MAPK activation but not ERK 1/2 acrivation by angiotensin II in rat aortic smooth muscle cells. Hypertens Res 2001;24:251-261.
25. Laakso M, Sarlund H, Salonen R, et al. Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb 1991;11:1068-1076.
26. Law RE, Meehan WP, Xi XP, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996;98:1897-1905.
27. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 1995;22:12953-12956.
28. Maeshiba Y, Kiyota Y, Yamashita K, Yoshimura Y, Motohashi M, Tanayama S. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 1997;47:29-35.
29. Mizushige K, Yao L, Noma T, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000;101:899-907.
30. Mizushige K, Noma T, Yao L, et al. Effects of troglitazone on collagen accumulation and distensibility of aortic wall in prestage of non-insulin-dependent diabetes mellitus of Otsuka Long-Evans Tokushima Fatty rats. J Cardiovasc Pharmacol 2000;35:150-155.
31. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease. Doppler echocardiography is the Clinician's Rosetta stone. J Am Coll Cardiol 1997;30:8-18.
32. Niskanen L, Rauramaa R, Miettinen H, Haffner SM, Mercuri M, Unsitupa M. Carotid artery intima-media thickness in elderly patients with NIDDM and in nondiabetic subjects. Stroke 1996;27:1987-1992.
33. Noma T, Mizushige K, Yao L, et al. Alteration in aortic wall stiffness and accumulation of collagen during the prediabetic stage of type II diabetes mellitus in rats. Jpn Circ J 1999;63:988-993.
34. Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998;101:1354-1361.
35. Olefsky JM. The effects of spontaneous obesity on insulin binding, glucose transport, and glucose oxidation of isolated rat adipocytes. J Clin Invest 1976;57:842-851.
36. Perez JE, McGill JB, Santiago JV, et al. Abnormal myocardial acoustic properties in diabetic patients and their correlation with the severity of disease. J Am Coll Cardiol 1992;19:1154-1162.
37. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 1992;70:593-599.
38. Reaven GM. Insulin resistance and compensatory hyperinsulinemia: Role in hypertension, dyslipidemia, and coronary heart disease. Am Heart. J 1991;121:1283-1288.
39. Regan TJ, Weisse AB. Diabetic cardiomyopathy. J Am Coll Cardiol 1992;19:1165-1166.
40. Rodrigues B, Mcneill JH. The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc Res 1992;26:913-922.
41. Salomaa V, Riley W, Kark JD, Nado C, Folsom AR. Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes: The ARIC study. Circulation 1995;91:1432-1443.
42. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-1669.
43. Suter SL, Nolan JJ, Wallace P, et al. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992;15:193-203.
44. Tian H, Ma A, Li C, Cheng M, Bai L, Liu H. Correlative factors of insulin resistance in essential hypertension. Hypertens Res 2000;23:265-270.
45. Tsuji T, Mizushige K, Noma T, et al. Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovacs Pharmacol 2001;38:868-874.
46. Vaziri ND, Ding Y, Ni Z, Gonick HC. Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced hypertension: Effect of lazaroid therapy. Kidney Int 1997;52:1042-1046.
47. Yagi K, Kim S, Wanibuchi H, Yamashita T, Yamamura Y, Iwao H. Characteristics of diabetes, blood pressure, and cardiac and renal complications in Otsuka Long-Evans Tokushima Fatty rats. Hypertension 1997;29:728-735.
48. Yamaji T, Fukuhara T, Kinoshita M. Increased capillary permeability to albumin in diabetic rat myocardium. Circ Res 1993;72:947-957.
49. Yasunari K, Kohno M, Kano H, Yokokawa K, Minami M, Yoshikawa J. Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells. Circ Res 1997;81:953-962.
50. Yasunari K, Kohno M, Kano H, Yokokawa K, Minami M, Yoshikawa J. Antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose. Circulation 1999;99:1370-1378.